There is 1 version of this bill. View text

Click the check-box to add or remove the section, click the text link to scroll to that section.
Titles Actions Overview All Actions Cosponsors Committees Related Bills Subjects Latest Summary All Summaries

Titles (2)

Short Titles

Short Titles - House of Representatives

Short Titles as Introduced

Medicare Fair Drug Pricing Act of 2018

Official Titles

Official Titles - House of Representatives

Official Title as Introduced

To amend part D of title XVIII of the Social Security Act to require the Secretary of Health and Human Services to determine, on behalf of Medicare beneficiaries, covered part D drug prices for certain covered part D drugs, and for other purposes.


Actions Overview (1)

Date Actions Overview
07/26/2018Introduced in House

All Actions (5)

Date All Actions
08/13/2018Referred to the Subcommittee on Health.
Action By: Committee on Ways and Means
07/27/2018Referred to the Subcommittee on Health.
Action By: Committee on Energy and Commerce
07/26/2018Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Action By: House of Representatives
07/26/2018Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Action By: House of Representatives
07/26/2018Introduced in House
Action By: House of Representatives

Cosponsors (0)

No cosponsors.


Committees (2)

Committees, subcommittees and links to reports associated with this bill are listed here, as well as the nature and date of committee activity and Congressional report number.

Committee / Subcommittee Date Activity Reports
House Energy and Commerce07/26/2018 Referred to
House Energy and Commerce Subcommittee on Health07/27/2018 Referred to
House Ways and Means07/26/2018 Referred to
House Ways and Means Subcommittee on Health08/13/2018 Referred to

No related bill information was received for H.R.6574.


Subjects (6)


Latest Summary (1)

There is one summary for H.R.6574. View summaries

Shown Here:
Introduced in House (07/26/2018)

Medicare Fair Drug Pricing Act of 2018

This bill requires the Centers for Medicare & Medicaid Services (CMS) to negotiate with drug manufacturers in determining the price that may be charged for prescription drugs under the Medicare prescription drug benefit.

Under current law, the CMS may not interfere with negotiations between drug manufacturers and prescription drug plan (PDP) sponsors. The bill creates an exception to this prohibition with respect to specified drugs that: (1) are single-source or biological, (2) are not both manufactured by more than two drug manufacturers and manufactured by at least one manufacturer as a generic drug, and (3) meet other specified requirements. The CMS must promulgate regulations regarding the identification of such drugs.

With respect to these drugs, the CMS shall negotiate the price that may be charged to PDP sponsors and Medicare Advantage (MA) organizations for Medicare and MA enrollees. The bill establishes processes for negotiation and price determination in the initial plan year and subsequent plan years.

A manufacturer must participate in the negotiation process as a condition of coverage under the Medicare prescription drug benefit.